Genetische tests voor maagkanker
After nearly ten years of development, tumor genetic testing has become the immediate need of a large number of cancer patients. The test report guidance provided by tumor genetic testing perfectly fits the development concept of precision medicine, and has penetrated into all aspects of the diagnosis and treatment of tumor patients. For patients, they can choose targeted drugs for precise treatment, avoid detours, and avoid unnecessary side effects. bitter.
Huidige status van gerichte therapie voor maagkanker
In most cases, surgery is still the main treatment for gastric cancer. However, the heterogeneity of gastric cancer is very strong, and its biological behavior is affected by the huge gene regulation in the cell. Therefore, only by classifying the essential characteristics of gastric cancer from the molecular level can early diagnosis and prognosis judgment of the tumor be more reasonable and accurate , Application of molecular targeted drugs for individualized and precise treatment of patients.
Op dit moment zijn de volgende gerichte medicijnen goedgekeurd:
| Serienummer | doelwit | drug |
| 1 | HER2 | Trastuzumab (trastuzumab, herceptine) |
| 2 | VEGFR | Ramucirumab |
| 3 | NTRK | Larotrectinib (LOXO-101) |
| 4 | PD-1 | Pembrolizumab (K drug) |
| 5 | VEGFR-2 | Apatinib (Apatinib, Aitan) |
In addition, there are many other targeted drugs related to gastric cancer in clinical trials, such as drugs that block HER2: lapatinib (Tykerb ®), pertuzumab (Perjeta ®) and trastuzumab emtansine (Kadcyla ®). Drugs that block EGFR: Panitumumab (Victibi®) is a drug that targets EGFR that is being tested for gastric cancer.
The Global Oncologist Network reminds everyone that genetic testing is required before targeted therapy . Only by understanding the type of tumor gene mutation can a reasonable treatment plan be developed to benefit patients. In addition, in the selection of genetic testing technology, it is necessary to select the appropriate testing technology according to its corresponding target . Only by choosing products approved by the State Food and Drug Administration can the accuracy and reliability of the test results be guaranteed.
Hoe kiezen patiënten met maagkanker voor genetisch onderzoek?
The Global Oncologist Network reminds patients that cancer genetic testing and clinical treatment analysis are a systematic project that requires strong laboratory support, high-standard testing quality control and a high-level data analysis team. A good genetic test analysis can avoid the loss of treatment opportunities and save the lives of cancer patients. At present, there are dozens of genetic testing institutions on the market, and patients must carefully select genetic testing companies to ensure the accuracy of the test results.
Hier is een genetische testtechnologie die is goedgekeurd door de FDA!
FoundationOne®CDx
FoundationOne®CDx werd door de FDA goedgekeurd als het eerste begeleidende diagnostische product van het pan-tumortype . As a research tool, it assisted the discovery of countless scientific research results, and accumulated a large amount of data during this period. The current test coverage includes 324 genes and two molecular markers (MSI / TMB) that can predict the efficacy of immune checkpoint inhibitors. It can cover all solid tumors (except sarcoma) and can directly correspond to 17 gerichte therapieën goedgekeurd door de FDA!
For clinical evaluation of cancer genes, commonly used techniques include Sanger sequencing, mass spectrometry genotyping, fluorescence in situ hybridization (FISH) and immunohistochemical analysis (IHC). “Standard single marker detection” such as FISH, IHC and multi-gene hotspot detection (hotspot panel) can only find one or two types of clinically significant genetic abnormalities (such as only base substitutions). Studies have shown that the latest comprehensive next-generation sequencing technology for cancer comprehensive genetic testing can detect all four types of genetic abnormalities (base replacement; insertion and deletion; copy number variation and rearrangement), and is more accurate than traditional, standard tests.
Hoe kunnen kankerpatiënten de FoundationOne® CDx-test ondergaan?
In China is het een analysedienst die wordt aangeboden door Dean Diagnostics. Global Oncologist Network kan kankerpatiënten helpen om deze dienst te ontvangen, of genetische tests voor binnenlandse gezaghebbende certificering. Global Oncologist Network, als een bekend binnenlands kankerpatiëntenserviceplatform, is het oncologiecentrum en bekende kankerexperts werken nauw samen om regelmatig grootschalige arts-patiëntuitwisselingsbijeenkomsten en populair-wetenschappelijke lezingen te organiseren om patiënten te helpen gestandaardiseerd te worden en gezaghebbende diagnose- en behandelplannen door middel van deskundig overleg in binnen- en buitenland, en het genezingspercentage verbeteren. We zullen ons ook voortdurend blijven inspannen om 's werelds meest toonaangevende informatie, technologie, experts, medicijnen, klinische proeven, enz. ter wereld te introduceren en alles in het werk te stellen om meer patiënten betere kankerbestrijdingsdiensten te bieden.
KankerFax als een bekend advies- en serviceplatform voor de diagnose en behandeling van kanker in eigen land, zet zich in voor het leveren van eersteklas kankerbestrijdingsdiensten voor binnenlandse kankerpatiënten, inclusief de nieuwste kankerbestrijdingstechnologie en middelen van topkankerexperts, het opzetten van de grootste tumor consultatie- en adviescentrum in India, en samenwerken met beroemde tumorconsultatiecentra en experts in de Verenigde Staten, China, Israël en Europa om de meest betrouwbare tumordiagnose en -behandelingsadviesexpert ter wereld te worden.
